170 related articles for article (PubMed ID: 36822245)
1. Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study.
Kinjo M; Masuda K; Nakamura Y; Miyakawa J; Tambo M; Fukuhara H
Urology; 2023 May; 175():67-73. PubMed ID: 36822245
[TBL] [Abstract][Full Text] [Related]
2. Comparison of mirabegron and vibegron for clinical efficacy and safety in female patients with overactive bladder: a multicenter prospective randomized crossover trial.
Wada N; Mizunaga M; Abe N; Miyauchi K; Kobayashi S; Ohtani M; Tsunekawa R; Nagabuchi M; Morishita S; Ohyama T; Yamaguchi S; Iuchi H; Noda T; Saga Y; Motoya T; Kawakami N; Nishihara M; Numata A; Kakizaki H
World J Urol; 2024 Mar; 42(1):113. PubMed ID: 38431689
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison.
Kennelly MJ; Rhodes T; Girman CJ; Thomas E; Shortino D; Mudd PN
Adv Ther; 2021 Nov; 38(11):5452-5464. PubMed ID: 34537953
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296
[TBL] [Abstract][Full Text] [Related]
5. Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study.
Shin DG; Kim HW; Yoon SJ; Song SH; Kim YH; Lee YG; Joo KJ; Bae JH; Kang TW; Jeong SJ; Woo SH; Yoo ES; Son H; Koo KC; Kim SW
Neurourol Urodyn; 2019 Jan; 38(1):295-304. PubMed ID: 30311691
[TBL] [Abstract][Full Text] [Related]
6. Vibegron, a Novel Potent and Selective β
Yoshida M; Takeda M; Gotoh M; Nagai S; Kurose T
Eur Urol; 2018 May; 73(5):783-790. PubMed ID: 29366513
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study.
Zhao L; Wu F; Wang J; Wang Y; Peng W; Chen Y
World J Urol; 2024 Jun; 42(1):370. PubMed ID: 38847900
[TBL] [Abstract][Full Text] [Related]
8. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study).
Nakagomi H; Mitsui T; Shimura H; Ihara T; Kira S; Sawada N; Takeda M
BMC Urol; 2022 Mar; 22(1):40. PubMed ID: 35313873
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of vibegron, a novel β3-adrenoreceptor agonist, on severe urgency urinary incontinence related to overactive bladder: post hoc analysis of a randomized, placebo-controlled, double-blind, comparative phase 3 study.
Yoshida M; Takeda M; Gotoh M; Yokoyama O; Kakizaki H; Takahashi S; Masumori N; Nagai S; Minemura K
BJU Int; 2020 May; 125(5):709-717. PubMed ID: 31991511
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
[TBL] [Abstract][Full Text] [Related]
12. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of vibegron for the treatment of overactive bladder in the United States.
Chen JV; Klein TM; Nesheim J; Mudd PN
J Med Econ; 2022; 25(1):1092-1100. PubMed ID: 35993729
[TBL] [Abstract][Full Text] [Related]
14. A multicenter prospective study for overactive bladder patient treatment satisfaction with mirabegron after being unsatisfied with antimuscarinic therapy (FAVOR study).
Ko KJ; Choo MS; Chang YS; Kim JC; Lee KS
Neurourol Urodyn; 2020 Nov; 39(8):2417-2424. PubMed ID: 32894793
[TBL] [Abstract][Full Text] [Related]
15. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
Cho SY; Jeong SJ; Lee S; Kim J; Lee SH; Choo MS; Oh SJ
Neurourol Urodyn; 2021 Jan; 40(1):286-294. PubMed ID: 33389776
[TBL] [Abstract][Full Text] [Related]
16. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.
Chen SF; Kuo HC
Low Urin Tract Symptoms; 2019 Apr; 11(2):O53-O58. PubMed ID: 29380517
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
Low Urin Tract Symptoms; 2019 Apr; 11(2):O65-O70. PubMed ID: 29473309
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: A randomized controlled trial (COMFORT study).
Otsuka A; Kageyama S; Suzuki T; Matsumoto R; Nagae H; Kitagawa M; Furuse H; Ozono S
Int J Urol; 2016 Dec; 23(12):1016-1023. PubMed ID: 27686226
[TBL] [Abstract][Full Text] [Related]
20. Mirabegron versus vibegron in previously untreated female patients with overactive bladder: A randomized, single-clinic, open-label trial.
Sato H; Otsuka S; Tsukada S
Low Urin Tract Symptoms; 2023 Jul; 15(4):129-138. PubMed ID: 37143383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
